Torrent Pharmaceuticals Limited is expanding its recall once again for Losartan potassium tablets and Losartan potassium/ hydrochlorothiazide tablets because they contain "N-Methylnitrosobutyric acid (NMBA), a potential cancer-causing impurity, above the acceptable daily intake levels released by the FDA," according to the U.S. Food and Drug Administration website.
The recall was expanded to include 36 lots of Losartan potassium tablets and 68 lots Losartan potassium/ hydrochlorothiazide tablets. The tablets treat hypertension and hypertensive patients with Left Ventricular Hypertrophy and nephropathy in Type 2 diabetic patients.
For a full list of the tablets affected by the recall, click here.
Patients "should continue taking their medication, as the risk of harm to the patient’s health may be higher if the treatment is stopped immediately without any alternative treatment."
Consumers with medical questions regarding this recall or to report an adverse event can contact Torrent Pharmaceuticals Limited at:
- 1-800-912-9561 (live calls received 8:00 am – 5:00 pm Eastern Time, voicemail available 24 hours/day, 7 days/week).
- Medinfo.Torrent@apcerls.com
Any general questions regarding the return of this product should be directed to Qualanex at 1- 888-280-2040 (live calls received 8 am - 9:00 pm Eastern Time).
To read the full release, click here.
